Order — ECLI:EU:C:2017:171
Date: 2017-03-02
Language of the case: Czech
Court formation: Eighth Chamber
Subject matter: Justice and home affairs;Approximation of laws;Public health
Procedure: Reference for a preliminary ruling
Origin: Czechia

Summary — Order of the Court (Eighth Chamber), 2 March 2017 Approximation of laws — Monitoring of trade in drug precursors — Regulations No 273/2004 and No 111/2005 — Scope — Scheduled substances — Definition — Medicinal products within the meaning of Directive 2001/83 — Not included (European Parliament and Council Regulations No 273/2004, as amended by Regulation No 1258/2013, Art. 2(a) and No 1259/2013; European Parliament and Council Directive 2001/83, as amended by Directive 2004/27, Art. 1(2)) ‘Medicinal products’, within the meaning of Article 1(2) of Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use, as amended by Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, which contain ‘scheduled substances’, within the meaning of Article 2(a) of Regulation (EC) No 273/2004 of the European Parliament and of the Council of 11 February 2004 on drug precursors, as amended by Regulation (EU) No 1258/2013 of the European Parliament and of the Council of 20 November 2013, such as ephedrine and pseudoephedrine, remain excluded from the scope of Regulation No 273/2004 following the entry into force of Regulation No 1258/2013 and Regulation (EU) No 1259/2013 of the European Parliament and of the Council of 20 November 2013 amending Council Regulation (EC) No 111/2005 laying down rules for the monitoring of trade between the Union and third countries in drug precursors. (see para. 35, operative part)